Walgreens plans to sell a variety of CBD products in 1,500 stores. Products to be sold in Oregon, Colorado, New Mexico, Kentucky, Tennessee, Vermont, South Carolina, Illinois, and Indiana include CBD creams, patches, and sprays. CVS shared similar plans at the start of March. (CNBC)

Johnson & Johnson has been cleared of liability by a New Jersey jury in a talc-related lawsuit. In it, a man alleged asbestos caused his mesothelioma. This is one of nearly 13,000 similar lawsuits J&J currently faces nationwide in relation to potential asbestos in the company’s talc-based products, including its baby powder. (Reuters)

U.S. health insurer Centene Corp plans to buy WellCare Health Plans for $15.3 billion in stock and cash. The move comes after the Trump Administration’s announcement opposing the Affordable Care Act. Since nearly 40% of Centene’s earnings stem from Obamacare, the acquisition would bolster its Medicare and Medicaid business. (Reuters)

Pain Therapeutics has rebranded as Cassava Sciences and shifted its therapeutic focus to Alzheimer’s disease. The drugmaker’s treatment PTI-125 is meant to slow the disease’s progression by addressing neuronal function, reducing neuroinflammation, and improving cognition. The company plans to release Phase IIa results in 2019. (Endpoints)

David Weingard, founder and CEO of Cecelia Health, shares how digital health is powering pharma patient support. He also gives a preview of “The Future of Value-Based Reimbursement and Care,” the panel he’s moderating at the MM&M Transforming Healthcare conference on May 8 in NYC. (MM&M)

Check out the latest speaker additions to the lineup to the MM&M Transforming Healthcare conference.